Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isovue 370 vs. Visipaque 320 in Coronary CTA
NCT02171247Phase 3
Key facts
- Status
- Completed
- Start
- Apr 2008
- Primary completion
- Dec 2010
- Sponsor
- Duke University
- Modality
- Small Molecules
- Drugs
- iopamidol
- Conditions
- coronary artery disease (CAD)
01
Overview
Phase 3, randomised trial of iopamidol in coronary artery disease (CAD), sponsored by Duke University. Primary endpoints: Contrast to Noise Ratio at 3 hours, Image Quality at 3 hours and 1 more. Started Apr 2008; status: completed.
02
Design
- Study design
- Randomized
03
Endpoints
Primary
Contrast to Noise Ratio
Image Quality
Motion Artifact
Beyond the preview
Go deeper on NCT02171247.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171247.